Trials / Terminated
TerminatedNCT01857817
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Vicus Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VT-122 | The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules. |
| DRUG | Placebo | The placebo capsules will be prepared to match the active drug. |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2013-05-20
- Last updated
- 2018-04-26
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01857817. Inclusion in this directory is not an endorsement.